“The main players operating in this market are F. Hoffmann-La Roche Ltd. (Switzerland), Myriad Genetics, Inc. (USA), QIAGEN NV (Netherlands), Thermo Fisher Scientific, Inc. (USA). USA), Guardant Health, Inc. (USA), MDxHealth SA (Belgium)”
In August 2022, Thermo Fisher Scientific Inc. (USA) launched the first NGS-based tests to support DNA and RNA input. The Ion Torrent Oncomine Myeloid MRD (RUO) assays provide comprehensive and highly sensitive measurable myeloid residual (MDR) assessments from blood and bone marrow samples.
Liquid Biopsy Market it is projected to reach $10 billion by 2027 from $4.3 billion in 2022, at a CAGR of 18.3% according to a new report from MarketsandMarkets™. Rising incidence and prevalence of various types of cancer, improvements in liquid biopsy technology, increasing demand for non-invasive procedures, and promising government initiatives enhance market growth. However, the lack of awareness about cancer and its risk factors, coupled with reduced access to advanced cancer diagnostic technologies in developing regions, is expected to hamper the growth of the market. Furthermore, the advantages of liquid biopsy over conventional invasive diagnostic methods are expected to present lucrative growth opportunities for the market.
Download brochure in PDF: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=13966350
Browse detailed TOC on “Liquid Biopsy Market”
208 – Tables
50 – Figures
271 – Pages
The increasing prevalence of cancer, coupled with the increasing demand for rapid and minimally invasive diagnostic tests, drives the growth of the market. The rapid development of digital polymerase chain reaction (PCR) and NGS-based technology has improved the accuracy of liquid biopsy. It can be performed repeatedly for disease control and is expected to help overcome the limitations of tissue biopsies.
The assay kits segment accounted for the largest share of the liquid biopsy market, by product and service segment, in 2021
Based on the product and service, the liquid biopsy market is segmented into test kits, instruments, and services. The bulk of the test kit segment can be attributed to the recurring requirement and large purchases of test kits among end users.
Segment of circulating tumor DNA (ctDNA) to record the highest growth rate during the forecast period
The liquid biopsy market is segmented into circulating tumor cells, circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), extracellular vesicles (EVS), and other circulating biomarkers. The studies found that detection of gene mutations using ctDNA is highly sensitive and specific, suggesting that ctDNA analysis can significantly improve tumor diagnosis, even facilitating early-stage detection. The superiority of ctDNA over previous plasma biomarkers in sensitivity and clinical correlations is an important factor driving its growth.
Request sample pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=13966350
Blood Sample Accounted for the Most Liquid Biopsy, by Sample Type Segment, in 2021
Based on the sample type, the liquid biopsy market is segmented into blood and other sample types. In 2021, blood samples accounted for the largest share of the liquid biopsy market. Much of this segment can be attributed to factors such as the convenient, economical, safe, and minimally invasive nature of this type of sample.
North America is the largest regional market for the liquid biopsy market
The global liquid biopsy market has been segmented into four main regions: North America, Europe, Asia Pacific, and the Rest of the World. In 2021, North America accounted for the largest share of the liquid biopsy market. The easy accessibility and high adoption of advanced diagnostic technologies among healthcare professionals and the increasing prevalence of cancer in the US and Canada are the key factors driving the growth of the liquid biopsy market in North America.
The main players operating in this market are F. Hoffmann-La Roche Ltd. (Switzerland), Myriad Genetics, Inc. (USA), QIAGEN NV (Netherlands), Thermo Fisher Scientific, Inc. (USA). .), Guardant Health, Inc. (USA), MDxHealth SA (Belgium), Exact Sciences Corporation (USA), Illumina Inc. (USA), Sysmex Inostics (USA), Bio-Rad Laboratories, Inc. (USA), Biocept, Inc. (USA), NeoGenomics, Inc. (USA), ANGLE plc (UK), Menarini-Silicon Biosystems (Italy) , Vortex Biosciences, Inc. (USA), Exosome Diagnostics, Inc. (USA), Agena Bioscience, Inc. (USA), MedGenome Inc. (USA), Epigenomics AG ( Germany) and Personal Genome Diagnostics, Inc. (USA).
Get 10% free customization on this report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=13966350
Media contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact person: Mister. Ashish Mehra
Email: Send an e-mail
Telephone: 18886006441
Address:630 Dundee Road Suite 430
City: northbrook
Condition: IL 60062
Country: USA
Website: https://www.marketsandmarkets.com/Market-Reports/liquid-biopsy-market-13966350.html
